Introduction {#Sec1}
============

In late 2019, a cluster of pneumonia cases reported in Wuhan (China) was associated with a novel coronavirus, initially called the 2019 novel coronavirus (2019-nCov) \[[@CR1]\]. Posteriorly, the sequence of the 2019-nCov genome revealed high similarity to SARS-CoV, the causative agent of the epidemic of severe and acute respiratory syndrome (SARS) between 2002 and 2003 in Asia. Then, the International Committee on Taxonomy of Viruses (ICTV) renamed 2019-nCov as SARS-CoV-2, and the World Health Organization (WHO) defined that this pathogen causes the coronavirus disease of 2019 (COVID-19) \[[@CR2]--[@CR5]\].

SARS-CoV-2 is responsible for a respiratory infection that can progress to severe pneumonia. COVID-19 has an estimated mortality rate of approximately 2--3.5%, which increases with age and the presence of comorbidities (*e.g.,* hypertension, cardiac insufficiency, diabetes, and asthma). By April 15, 2020, the novel coronavirus had affected 2,033,406 people and caused more than 130,000 deaths worldwide \[[@CR6]\]. The public health calamity caused by COVID-19 has led to the exhaustion of health systems worldwide, forcing countries to adopt extreme measures, such as the closure of their land borders and initiating social distancing policies to slow down the spread of the disease \[[@CR7]\].

Currently, laboratories and medical teams worldwide have focused on the repurposing of Food and Drug Administration (FDA)-approved drugs to treat the most severe cases of COVID-19, since there are no specific chemotherapeutic agents to treat this infection \[[@CR1]\]. Indeed, drug repositioning might be a short-term alternative to fight this disease. Since the efficacy, safety, and toxicity of these drugs are already well known, the initial phases of clinical trials could be skipped, which would reduce the cost and duration of the process \[[@CR8]\]. In general, drug repurposing is a cheaper, faster, and accessible way to make drugs available to the clinic \[[@CR9], [@CR10]\].

In this context, several clinical and preclinical studies have searched for new pharmacological alternatives against COVID-19 in clinically available drugs. However, current studies remain decentralized, and no recent review has been able to summarize the available evidence of the anti-SARS-CoV-2 activity of these FDA-approved drugs. Thus, in this systematic review, we aim to describe the drug repositioning strategy against SARS-CoV-2 and its clinical impact in the current context of the COVID-19 pandemic.

Methods {#Sec2}
=======

We performed a systematic review according to the Cochrane Handbook \[[@CR11]\]. The search and selection of articles, as well as extraction, analysis, and interpretation of data, were conducted according to the *Preferred Reporting Items for Systematic Reviews and Meta-Analyses* (PRISMA) statement \[[@CR12]\]. PubMed/MEDLINE, Scopus, Cochrane Library, and *Biblioteca Virtual de Saúde* (BVS) were searched for articles investigating the antiviral activity of clinically available drugs published until March 23, 2020. We aimed to select articles describing clinical and pre-clinical tests (*in vitro*, *in vivo,* and *in silico*) to include the largest amount of data in this review. Additionally, we searched the Clinicatrial.gov website to identify ongoing trials with potential candidates for the drug repositioning strategy against SARS-CoV-2.

Indexed keywords from Medical Subject Headings (MeSH) were used to build search strategies. The terms "Antiviral agents" OR "Drug Repositioning" OR "Drug repurposing" were combined with the keywords "COVID-19" OR "SARS-CoV-2" OR "2019-nCoV" by the use of Boolean AND between the terms, as in the example: "Drug Repositioning" AND "COVID-19". All details about the search strategies can be found in the supplementary file. To avoid losing any possible study, the reference list of all included studies and relevant reviews regarding this topic were also screened.

Two authors (W.G.L. and J.C.M.B.) independently screened the databases and extracted relevant information following the PRISMA flowchart. The degree of agreement between the evaluators was determined by the kappa coefficient (performed with a 95% confidence interval) \[[@CR13]\]. Discrepancies about the relevance of the sources were resolved by a third researcher (W.S.C.N.). Finally, all data of interest were summarized in tables (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}) for further critical analysis and interpretation.Table 1Clinical evidence of potential candidates for drug repositioning against COVID-19 (SARS-CoV-2)ReferenceDrugsStudy design and countryNo. of patientsMain outcomesWang et al., 2020 \[[@CR14]\]Lopinavir/ritonavirUmifenovir\*Retrospective studyChina4Recovery and restoration of immune function, improvement of pulmonary imaging findings, promotion of a negative conversion of viruses, and an increase in the oxygen pressure were observed after the antiviral treatment.Mo et al., 2020 \[[@CR16]\]Lopinavir/ritonavirUmifenovir\*\*Retrospective studyChina45Only supportive care (oxygen, fluid control and mechanical ventilation) was associated with patient recovery.Shi et al., 2020 \[[@CR25]\]GanciclovirOseltamivir^\#^Case reportChina1The antiviral treatment resulted in an improvement of pulmonary imaging findings.Holshue et al., 2020 \[[@CR17]\]Remdesivir^\#^Case reportUSA1Improvements in pulmonary imaging findings and an increase in oxygen pressure were observed after the treatment with remdesivir.Cao et al., 2020 \[[@CR15]\]Lopinavir/ritonavir\*\*\*Randomized, controlled, open-label clinical trialChina199Treatment with lopinavir/ritonavir did not improve the clinical condition of patients compared to the standard of care\*\*\*\*Lopinavir (400 mg) + ritonavir (100 mg), q12h, orally; associated with umifenovir (200 mg), q12h, orally. The duration of antiviral treatment was 6-15 days\*\*Solution containing umifenovir (20.0%), lopinavir + ritonavir (17.4%) and interferon (19.4%) administered through inhalation\*\*\*In this study, 99 patients were assigned to receive lopinavir/ritonavir (400 mg and 100 mg, orally), and 100 patients were assigned to the standard of care (oxygen supplementation, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation)^\#^In these studies, the therapeutic scheme used was not clearly definedTable 2*In vitro* activity of promising candidates for drug repositioning against COVID-19 (SARS-CoV-2)ReferenceDrugClinical indicationAntiviral activityCytotoxicity (CC~50~; μM)MOIEC~50~ (μM)Wang et al., 2020 \[[@CR18]\]RemdesivirAntiviral (Ebola)0.050.77\> 100RibavirinAntiviral (hepatitis C)0.02109.50\> 400PenciclovirAntiherpetic0.295.96\> 400NitazoxanideAntiprotozoal agent0.82.12\> 35.5NafamostatAnticoagulant0.0122.50\> 100FavipiravirAntiviral (RNA virus)0.0295.96\> 400ChloroquineAnti-malarial0.011.13\> 100Liu et al., 2020 \[[@CR19]\]ChloroquineAnti-malarial0.012.71273.20HydroxychloroquineAnti-malarial0.014.51249.50MOI, multiplicity of infection; EC50, concentration of drug required to inhibit 50% of viruses; CC50, concentration of drug required to kill 50% of mammalian cellsAll studies employed Vero E6 cellsTable 3*In silico* activity of promising candidates for drug repositioning against COVID-19 (SARS-CoV-2)ReferenceCompoundClinical indication*In silico* methodsMolecular targetComputational methodChen et al., 2020 \[[@CR20]\]VelpatasvirAntiviral (hepatitis C)SASR-CoV-2 protease (3CLpro)Molecular docking (AutoDock Vina)LedipasvirAntiviral (hepatitis C)DiosminVenous insufficiencyHesperidinVenous insufficiencyTeniposideAntitumoralEtoposideAntitumoralVenetoclaxAntitumoralIrinotecanAntitumoralXu et al., 2020 \[[@CR21]\]NelfinavirAntiretroviralSASR-CoV-2 protease (3CLpro)Molecular docking (AutoDock Vina)PitavastatinHipolipemiantPerampanelAntiepilepticPraziquantelAnthelminticZopicloneSedative hypnoticEszopicloneSedative hypnoticLiu and Wang, 2020 \[[@CR23]\]ValrubicinAntitumoralSASR-CoV-2 protease (3CLpro)Molecular docking (AutoDock Vina)IcatibantAngioedemaBepotastineAntiallergicEpirubicinAntitumoralEpoprostenolAntiplatelet agentVapreotideAntitumoralAprepitantAntiemetic, antitumoralCaspofunginAntifungalPerphenazineAntipsychoticColistinAntibioticLi et al., 2020 \[[@CR22]\]NelfinavirAntiretroviralSASR-CoV-2 protease (3CLpro)Molecular docking (AutoDock Vina)PrulifloxacinAntibioticBictegravirAntiretroviralTegobuvirAntiviral (hepatitis C)Beck et al., 2020 \[[@CR24]\]AtazanavirAntiretroviralRdRp, helicaseMT-DTI modelGanciclovirAntiretroviralDarunavirAntiretroviral3CLpro, 3-chymotrypsin-like protease; RdRp, RNA-dependent RNA polymerase; MT-DTI, Molecule Transformer-Drug Target InteractionTable 4Clinical trials of promising candidates for drug repositioning against COVID-19 (SARS-CoV-2)IDPopulationDrugIndicationPhaseNCT04292899400RemdesivirAntiviral (Ebola and Marburg)IIINCT04273529100ThalidomideImmunomodulatory agent, antiangiogenic, TNF blocking agent.IINCT0430831760TetrandrineAnti-inflammatory, immunologic and antiallergenicIVNCT04318015400HydroxychloroquineAntimalarial and anti-inflammatory (Rheumatoid arthritis and lupus)IIINCT04316377202ChloroquineAntimalarial and anti-inflammatory (Rheumatoid arthritis and lupus)IVNCT04260594380Umifenovir (Arbidol)Antiviral (influenza)IVNCT04286503520CarrimycinAntibiotic (macrolide)IVNCT0430329980OseltamivirAntiviral (influenza)IIINCT0430329980FavipiravirAntiviral (influenza)IIINCT04311177516LosartanAntihypertensiveIINCT0427541420BevacizumabAntitumoral (anti-VEGF)IINCT0431169720AviptadilErectile dysfunction treatmentIINCT04305457240Nitric oxide GasPulmonary hypertension treatmentIINCT0432027760BaricitinibAnti-inflammatory (rheumatoid arthritis)IIINCT0429172911DanoprevirAntiviral (hepatitis C)IVNCT04286503520RitonavirAntiretroviralIVNCT04288713-EculizumabHemolytic-uremic syndrome and paroxysmal nocturnal hemoglobinuria treatment-NCT04317092330TocilizumabRheumatoid arthritis treatmentIINCT04286503520LopinavirAntiretroviralIVNCT0427668870RibavirinAntiviral (hepatitis C)IINCT04315298400SarilumabRheumatoid arthritis treatmentIIAll data were obtained from a manual search in clinicaltrial.gov

Results {#Sec3}
=======

Study selection {#Sec4}
---------------

As shown in Figure [1](#Fig1){ref-type="fig"}, we identified 33 articles during the initial search (30 from PubMed/MEDLINE, two from *Biblioteca Virtual de Saúde*, and one from Scopus). After the exclusion of repeated records and the selection of articles by the inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}), 15 relevant studies were pre-selected. Of these, 11 were excluded following the criteria described in Figure [1](#Fig1){ref-type="fig"}, and four were selected for extraction of variables of interest \[[@CR14]--[@CR17]\]. The reference lists of included articles were analyzed, and eight new studies were identified \[[@CR18]--[@CR25]\], totaling 12 papers \[[@CR14]--[@CR25]\]. The degree of agreement between the two authors was considered substantial (kappa = 0.825) \[[@CR13]\].Fig. 1Flowchart of the selection of articles for the systematic review following the PRISMA criteria \[[@CR12]\]

Characteristics of included studies {#Sec5}
-----------------------------------

All selected studies were published in 2020, and they describe a total of 57 drugs that showed some evidence of antiviral activity against SARS-CoV-2 (Fig. [2](#Fig2){ref-type="fig"} and Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}) \[[@CR14]--[@CR25]\]. As shown in Figure [2](#Fig2){ref-type="fig"}A, 22 different classes of drugs showed a potential therapeutic effect against COVID-19. Antivirals, especially antiretrovirals, were the most frequently studied class of therapeutic agents (30%; 17/57). However, the activity of antitumor (16%; 9/57), antimalarial (7%, 4/57), antibacterial (5%; 3/57), anticoagulant (3.5%; 2/57), anti-inflammatory (3.5%; 2/57), phosphodiesterase (PDE)-inhibiting (3.5%; 2/57), anti-rheumatic (3.5%; 2/57), sedative-hypnotic (3.5%; 2/57), and anti-venous insufficiency (3.5%; 2/57) agents was also investigated. Other classes of drugs have also been studied against SARS-CoV-2 (*i.e.*, anthelmintic, antiallergic, antiemetic, antiepileptic, antifungal, antihypertensive, antipsychotic, anti-hemolytic-uremic syndrome, anti-angioedema, lipid-lowering, immunomodulatory, and anti-pulmonary-hypertension drugs); however, only one agent of each class was evaluated (1/57, 1.7%) (Fig. [2](#Fig2){ref-type="fig"}A).Fig. 2(A) Number of drugs in each therapeutic class with clinical or preclinical evidence of activity against SARS-CoV-2. (B) Distribution of drugs currently studied against COVID-19 according to the type of study

Most of the drugs with potential activity against COVID-19 were identified by molecular docking (53%; 30/57) (Fig. [2](#Fig2){ref-type="fig"}B) \[[@CR20]--[@CR24]\] using the main protease (3CLpro) of SARS-CoV-2 as the molecular target (Table [3](#Tab3){ref-type="table"}). Moreover, 39% (22/57) (Fig. [2](#Fig2){ref-type="fig"}B) of the drugs showed an anti-COVID-19 effect in clinical trials (Table [4](#Tab4){ref-type="table"}), and 10% of them showed evidence of action in clinical practice (10%; 6/57) \[[@CR14]--[@CR17]\] (Table [1](#Tab1){ref-type="table"}). Additionally, 19% (11/57) \[[@CR18], [@CR19]\] (Fig. [2](#Fig2){ref-type="fig"}B) of the drugs studied showed antiviral activity *in vitro*. For instance, remdesivir showed the highest activity against SARS-CoV-2, inhibiting 50% of the virus at a concentration of 0.77 μM \[[@CR18]\], while ribavirin showed a less pronounced effect (109.50 μM) \[[@CR18]\] (Table [2](#Tab2){ref-type="table"}). Therefore, the antiviral activity of only 27 compounds (47%; 27/57) has been experimentally evaluated. The remaining 30 reported drugs were identified only by theoretical methods (*in silico*) and need proof of antiviral efficacy in further studies (Table [3](#Tab3){ref-type="table"}).

Regarding the clinical trials of new therapeutic options against COVID-19, most drugs are in phase II (36%; 8/22) or III (27%; 6/22) (Table [4](#Tab4){ref-type="table"}). Only seven drugs (chloroquine, tetrandrine, umifenovir (arbidol), carrimycin, damageprevir, lopinavir/ritonavir) are in phase IV of clinical trials (Table [4](#Tab4){ref-type="table"}). Interestingly, two of these agents in advanced clinical studies, umifenovir (Arbidol) and the association lopinavir/ritonavir, have demonstrated previous evidence of action. Wang et al. \[[@CR14]\] reported that the use of arbidol in combination with lopinavir/ritonavir inhibits the aggravation of pneumonia caused by SARS-CoV-2 and promotes a virus-negative conversion in patients from China. Arbidol has also shown a potent *in vitro* effect against SARS-CoV-2, inhibiting the virus up to 60 times compared to the untreated control at concentrations ranging from 10 to 30 μM \[[@CR26]\].

Discussion {#Sec6}
==========

The novel coronavirus (SARS-CoV-2), the causative agent of COVID-19, has quickly become a threat to the public health and economy worldwide \[[@CR7], [@CR27]\]. Recent clinical reports have shown that SARS-CoV-2 causes mild, self-limiting respiratory tract illness as well as severe progressive pneumonia, which can progress to multiorgan failure and death \[[@CR1]\]. Despite the severity of some cases, there are no current pathogen-specific antivirals available to treat this disease \[[@CR1]\]. Therefore, many studies have focused on the evaluation of the anti-SARS-CoV-2 activity of clinically available drugs \[[@CR1]\].

After the analysis of the selected studies, we identified 57 molecules with potential antiviral activity against SARS-CoV-2. Of these, only six drugs (lopinavir/ritonavir, umifenovir (arbidol), remdesivir, chloroquine, and hydroxychloroquine) have shown promising results in preclinical trials and have clinically lessened the symptoms of COVID-19. Since the other FDA-approved drugs reported in this review showed weak activity against COVID-19, we have chosen to discuss only the most promising molecules.

Lopinavir and ritonavir are antiretrovirals widely used as a combination drug to treat human immunodeficiency virus (HIV) infections. Lopinavir is an HIV type 1 aspartate protease inhibitor, and ritonavir increases its plasma half-life through the inhibition of cytochrome P450 \[[@CR28]\]. Previous studies showed that lopinavir inhibits the 3-chymotrypsin-like protease, which is involved in viral replication and is highly conserved among members of different viral species \[[@CR29]\]. Lopinavir inhibited the replication of MERS-CoV and SARS-CoV in Huh7 cells (human liver strain) in a dose-dependent manner, with an EC~50~ of 8.0 μM for both viruses \[[@CR29]\]. Moreover, lopinavir/ritonavir significantly reduced the mortality rate of mice infected with MERS-CoV, suggesting a strong *in vivo* antiviral effect \[[@CR30]\].

Little is known about the activity of lopinavir/ritonavir against SARS-CoV-2 and its effectiveness (Table [1](#Tab1){ref-type="table"}). For instance, Wang et al. \[[@CR14]\] showed that the use of lopinavir/ritonavir considerably improved the clinical condition of patients with COVID-19. However, arbidol, a broad-spectrum antiviral with activity against several enveloped and non-enveloped viruses (e.g., influenza virus, adenovirus, avian coronavirus, and hepatitis B and C viruses) \[[@CR31]\], was also administered to the patients (n = 4). The combination of lopinavir/ritonavir with arbidol makes it difficult to associate the observed antiviral effect to lopinavir/ritonavir or to its synergistic effect with arbidol. In contrast, Mo et al. \[[@CR16]\] showed that the clinical improvement of patients with COVID-19 was more associated with supportive measures, such as mechanical ventilation and oxygen supplementation, than with the use of lopinavir/ritonavir. Likewise, a study of 199 hospitalized adult patients with confirmed SARS-CoV-2 infection showed that the use of lopinavir/ritonavir does not increase the effectiveness of the standard treatment \[[@CR15]\]. These findings confirm that lopinavir/ritonavir has low clinical efficacy and is not a therapeutic option to treat COVID-19. However, the efficacy related to the use of these antiretrovirals as a combination therapy with other drugs should be elucidated in future studies.

Arbidol (umifenovir) is an anti-influenza agent that has been used in China and Russia for many years. It interacts with the viral hemagglutinin (HA) and inhibits the fusion of the viral particle with the plasma membrane \[[@CR32]\]. This drug inhibited crucial stages of the SARS-CoV-2 replication cycle *in vitro* in a concentration ranging from 10 to 30 μM \[[@CR26]\]. Also, a study has indicated that arbidol significantly lessened pneumonia associated with COVID-19 \[[@CR14]\]. These results have stimulated the initiation of clinical trials with this medicine (Table [4](#Tab4){ref-type="table"}). For instance, a Chinese group of the Ruijin Hospital is currently conducting a phase IV study to evaluate the efficacy and safety of arbidol hydrochloride tablets in treating pneumonia in 380 patients with COVID-19 (Clinicaltrial.gov, NCT04260594).

Previous *in vitro* studies have indicated that arbidol shows significant activity against other coronaviruses. Herein, a research group showed that this compound negatively affects the early stages of viral replication of SARS-CoV at a concentration of 50 μg/ml. This study also highlighted the stronger antiviral activity of arbidol mesylate compared to arbidol as an alkaline preparation \[[@CR33]\]. These preliminary results indicate that arbidol is a promising candidate for drug repositioning against SARS-CoV-2. However, further studies are required to assess the difference in the effectiveness of arbidol and arbidol mesylate in patients with COVID-19.

Remdesivir is a broad-spectrum prodrug developed to treat infections caused by Ebola virus and Marburg virus. Its active ingredient (GS-441524) decreases the production of RNA by interfering with viral RNA polymerase and evading proofreading by viral exonuclease \[[@CR34]\]. Recent studies have shown that remdesivir inhibits the replication of SARS-CoV and MERS-CoV in human lung cells \[[@CR35]\]. Wang et al. \[[@CR18]\] showed that remdesivir has potent activity against SARS-CoV-2 in kidney cells, with an EC~50~ of 0.77 μM. Additionally, this drug induced the clinical remission of the symptoms of COVID-19 in the first reported case in the USA (Table [1](#Tab1){ref-type="table"}) \[[@CR17]\]. Due to these promising results, a phase III clinical trial has evaluated the antiviral activity of remdesivir and its safety in patients with severe COVID-19. This study is assessing the ability of remdesivir to normalize body temperature and oxygen saturation in 400 hospitalized adult patients (Clinicaltrial.gov, NCT04292899). Therefore, the results of this clinical trial can guide the prescription of remdesivir as an anti-SARS-CoV-2 agent in the future.

Chloroquine and hydroxychloroquine are antimalarial agents widely used to treat rheumatic diseases and have also shown promising activity against COVID-19 \[[@CR36]\]. The first evidence of their antiviral effect against coronavirus was reported in 2004 when Keyaerts and collaborators showed that chloroquine inhibited the *in vitro* replication of SARS-CoV on Vero cells E6. In this study, chloroquine negatively affected SARS-CoV-2 at a concentration of 8 μM \[[@CR37]\]. Interestingly, chloroquine inhibited the virus when the cells were treated with the drug before or after exposure to SARS-CoV, suggesting prophylactic and therapeutic effects \[[@CR38]\]. This drug also affects the entry and replication of SARS-CoV-2, with an EC~50~ of 1.13 μM \[[@CR18]\]. Moreover, hydroxychloroquine, a less toxic derivative of chloroquine, is also able to inhibit the entry and replication of SARS-CoV-2 with an EC~50~ of 4.51 μM (Table [2](#Tab2){ref-type="table"}) \[[@CR19]\]. Additionally, the preclinical results have suggested that this antimalarial blocks the transport of SARS-CoV-2 from endosomes to endolysosomes, which is a process required to release the viral genome \[[@CR18], [@CR19]\].

The promising *in vitro* results of chloroquine and hydroxychloroquine have motivated the initiation of clinical studies of these substances (Table [4](#Tab4){ref-type="table"}). One of these studies evaluates the prophylactic effect of the oral use of chloroquine in 10,000 patients against SARS-CoV-2 (Clinicaltrial.gov, NCT04303507). Additionally, several clinical trials have evaluated the prophylactic use of hydroxychloroquine (Clinicaltrial.gov, NCT04318015, and NCT04318444), its therapeutic use in monotherapy (Clinicaltrial.gov, NCT04315896), or the effect of its combination with other antivirals (Clinicaltrial.gov, NCT04303299, NCT04321278 and NCT0430127, and NCT0430127 and NCT0430127) against COVID-19.

The rapid popularization of these preliminary results has led to a massive and irrational demand for chloroquine and hydroxychloroquine. In Brazil, for example, after the first reports of the clinical effectiveness of hydroxychloroquine against COVID-19, this drug quickly sold out in pharmacies, which has compromised patients who use this drug continually to treat autoimmune diseases. This irrational demand caused the *Agência Nacional de Vigilância Sanitária* (ANVISA) to include these two drugs in the list of controlled substances to prevent their use to treat COVID-19 without prescription or proof of effectiveness. This situation highlights the importance of controlling the release of preliminary results, especially in the panic scenario created by the pandemic.

Although several studies have identified clinically available agents that are active against SARS-CoV-2 infections, supportive therapy remains essential. For instance, mechanical ventilation and oxygen supplementation have been critical to the survival of patients with severe COVID-19. Mo et al. \[[@CR16]\] showed that that oxygen supplementation and noninvasive or invasive ventilation have generated similar results to the use of an antiretroviral with known *in vitro* activity against SARS-CoV-2. Additionally, Wang et al. \[[@CR14]\] showed that the clinical recovery of patients with COVID-19 is more associated with supportive therapies than with the use of antiviral agents. However, the identification of available drugs with anti-SARS-CoV-2 activity and their use in association with supportive therapies should be considered. Also, the development of faster diagnostic tools to test for COVID-19 might be crucial, since some of the candidates for drug repositioning must be administered early in the course of infection. Thus, better testing methodologies could lead to the early administration of drugs and improve the treatment of COVID-19.

Conclusion {#Sec7}
==========

The rapid spread of SARS-CoV-2 worldwide has put pressure on research centers to develop effective therapies and vaccines for the treatment of SARS-CoV-2. Drug repositioning is a promising short-term strategy in the fight against the novel coronavirus. However, supportive measures are essential mainly for severe COVID-19 patients, and the implementation of drug repositioning should be done only if the efficacy of the drugs have been proven. Although lopinavir/ritonavir had low anti-SARS-CoV-2 activity, arbidol, remdesivir, and chloroquine/hydroxychloroquine showed promising effects against this coronavirus. Therefore, the outcomes of the ongoing clinical trials are urgently needed to evaluate the best treatment options for COVID-19. Furthermore, additional studies of the antiviral activity of molecules that have shown a promising *in silico* effect may increase the therapeutic arsenal against the novel coronavirus.
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